What it sells
AI and Data for Cancer Therapeutics
Business model breakdown
Buyer: who owns the budget?
UnverifiedDrug-discovery and gene-therapy R&D teams at biotech/pharma.
Workflow: what inputs become what output?
Axis model generates regulatory DNA elements and predicts their function, aimed at safer gene and cell therapies; a data engine over predicted cell data.
Distribution: how it reaches customers
Gated access: "Get Access" button; no pricing shown.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-10-16 | — | $20M | Accel (lead), Zacua Ventures (lead) | news.google.com |
| 2026-10-16 | — | $20M | — | news.google.com |
| 2026-10-15 | — | $20M | Accel, Zacua | news.google.com |
| 2026-10-15 | — | $20M | — | news.google.com |
| 2026-10-15 | — | $20M | — | news.google.com |
| — | Y Combinator Winter 2026 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-17.